Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021.

clinical benefit immunotherapies life-years oncology

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
08 Feb 2024
Historique:
received: 24 07 2023
revised: 06 01 2024
accepted: 09 01 2024
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 9 2 2024
Statut: aheadofprint

Résumé

In France, the potential benefit of new treatments is initially evaluated by the Haute Autorité de Santé to determine reimbursement and pricing, but rarely afterwards. Although immunotherapies (ITs) have considerably improved the survival of patients, few data are available on their long-term benefit at a population-treated level. The present retrospective study aimed to assess the clinical benefit of ITs compared to the previous standards of care (SoCs) in France from 2014 to 2021. To do this, we analyzed all ITs from the anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] class used in monotherapy or in association with another treatment available in early access or reimbursed in France between 2014 and 2021, regardless of indication. The number of patients initiating an IT was retrieved by year, drug and indication. Using extrapolated Kaplan-Meier curves, utility scores and the population treated, the clinical benefit was expressed as the number of deaths prevented (DP), life-years (LYs) and quality-adjusted life years (QALYs) gained compared to previous SoC. Across the period, five ITs were marketed in 21 indications related to eight primary tumor sites. Between 2014 and 2021, 132 924 patients initiated an IT. By December 2021, 16 173 (13 804-17 141) deaths were delayed compared to previous SoC, mainly in lung cancer. Compared to their SoC, ITs provided a gain of 37 316 (33 581-41 048) additional LYs and 27 709 (23 784-30 450) additional QALYs. Lung cancer was the driver indication with 70.6% of LYs and 68.4% of QALYs gained followed by melanoma with 18.7% and 20.4% of the gain, respectively. Significant gains in DP, LYs and QALYs have been observed in France following the introduction of ITs.

Sections du résumé

BACKGROUND BACKGROUND
In France, the potential benefit of new treatments is initially evaluated by the Haute Autorité de Santé to determine reimbursement and pricing, but rarely afterwards. Although immunotherapies (ITs) have considerably improved the survival of patients, few data are available on their long-term benefit at a population-treated level. The present retrospective study aimed to assess the clinical benefit of ITs compared to the previous standards of care (SoCs) in France from 2014 to 2021.
MATERIALS AND METHODS METHODS
To do this, we analyzed all ITs from the anti-programmed cell death protein 1/programmed death-ligand 1 [anti-PD-(L)1] class used in monotherapy or in association with another treatment available in early access or reimbursed in France between 2014 and 2021, regardless of indication. The number of patients initiating an IT was retrieved by year, drug and indication. Using extrapolated Kaplan-Meier curves, utility scores and the population treated, the clinical benefit was expressed as the number of deaths prevented (DP), life-years (LYs) and quality-adjusted life years (QALYs) gained compared to previous SoC.
RESULTS RESULTS
Across the period, five ITs were marketed in 21 indications related to eight primary tumor sites. Between 2014 and 2021, 132 924 patients initiated an IT. By December 2021, 16 173 (13 804-17 141) deaths were delayed compared to previous SoC, mainly in lung cancer. Compared to their SoC, ITs provided a gain of 37 316 (33 581-41 048) additional LYs and 27 709 (23 784-30 450) additional QALYs. Lung cancer was the driver indication with 70.6% of LYs and 68.4% of QALYs gained followed by melanoma with 18.7% and 20.4% of the gain, respectively.
CONCLUSIONS CONCLUSIONS
Significant gains in DP, LYs and QALYs have been observed in France following the introduction of ITs.

Identifiants

DOI: 10.1016/j.esmoop.2024.102240 PMID: 38335904
pubmed: 38335904
pii: S2059-7029(24)00008-5
doi: 10.1016/j.esmoop.2024.102240
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102240

Informations de copyright

Copyright © 2024 Bristol Myers Squibb. Published by Elsevier Ltd.. All rights reserved.

Auteurs

V Grumberg (V)

Bristol Myers Squibb France, Rueil-Malmaison; Oncostat, U1018, CESP, Inserm, Paris-Saclay University, 'Ligue Contre le Cancer' Team, Villejuif. Electronic address: Valentine.grumberg@bms.com.

F-E Cotté (FE)

Bristol Myers Squibb France, Rueil-Malmaison.

E Giroux-Leprieur (E)

Department of Respiratory Diseases and Thoracic Oncology, Paris-Saclay University, UVSQ, EA4340, APHP-Hôpital Ambroise Paré, Boulogne Billancourt.

A-F Gaudin (AF)

Bristol Myers Squibb France, Rueil-Malmaison.

C Lebbé (C)

Université Paris Cite, APHP Dermato-oncology, Cancer Institute APHP Nord Paris Cité, INSERM U976, Saint Louis Hospital, Paris.

I Borget (I)

Oncostat, U1018, CESP, Inserm, Paris-Saclay University, 'Ligue Contre le Cancer' Team, Villejuif; Biostatistics and Epidemiology Office, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Classifications MeSH